Table 1.

Overall patient characteristics by tofacitinib formulation among patients with PsA and RA

	Tofacitinib IR		Tofacitinib MR		All tofacitinib
	N	% of case reports	N	% of case reports	N	% of case reports
PsA
Case reports	2601		2425		5026
Sex
Male	710	27.3	677	27.9	1387	27.6
Female	1850	71.1	1732	71.4	3582	71.3
Not reported	41	1.6	16	0.7	57	1.1
Age
Median (SD) [range], years	56.0 (12.85) [8.0–90.0]		56.0 (12.48) [0.50–88.0]		Not available
< 65 years	1885	72.5	1866	76.9	3751	74.6
≥ 65 years	575	22.1	525	21.6	1100	21.9
Not reported	141	5.4	34	1.4	175	3.5
Geographical region
North Americaa	1783	68.6	2352	97.0	4135	82.3
Europeb	421	16.2	13	0.5	434	8.6
Rest of the worldc	397	15.3	60	2.5	457	9.1

RA
Case reports	39,744		24,148		63,892
Sex
Male	6685	16.8	4156	17.2	10,841	17.0
Female	32,425	81.6	19,864	82.3	52,289	81.8
Not reported	634	1.6	128	0.5	762	1.2
Age
Median (SD) [range], years	61.0 (12.63) [0.25–98.0]		60.0 (12.33) [0.50–97.0]		Not available
< 65 years	23,175	58.3	16,030	66.4	39,205	61.4
≥ 65 years	14,631	36.8	7633	31.6	22,264	34.8
Not reported	1938	4.9	485	2.0	2423	3.8
Geographical region
North Americaa	28,730	72.3	22,468	93.0	51,198	80.1
Europeb	1903	4.8	19	0.1	1922	3.0
Rest of the worldc	9111	22.9	1661	6.9	10,772	16.9

IR immediate release, MR modified release, PsA psoriatic arthritis, RA rheumatoid arthritis, SD standard deviation

^aIncludes case reports from Canada, Puerto Rico, and the US

^bIncludes case reports from Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, and the UK

^cIncludes case reports from Argentina, Australia, Brazil, Chile, China, Colombia, Ecuador, Egypt, Hong Kong, India, Japan, Korea, Kuwait, Lebanon, Malaysia, Mexico, Morocco, New Zealand, Peru, Philippines, Saudi Arabia, Singapore, South Africa, Thailand, Tunisia, and the United Arab Emirates